In this issue:
Treatment strategy for rifampicin-susceptible TB
Nintedanib for IPF in the real world
Azithromycin vs. placebo for LRTIs associated with low procalcitonin
Renin-angiotensin-system inhibitors and COPD exacerbation risk
Long-term physical sequelae for MDR/XDR TB
HFNC reduces intubations in COVID-19 patients with acute respiratory failure
Discontinuation vs. continuation of hypertonic saline or dornase alfa in CF
US hospital variations in practices and outcomes for severe acute IPF exacerbations
Long-term outcomes for ICI-induced pneumonitis
Cough desensitisation for refractory chronic cough
Please login below to download this issue (PDF)